JP2023551668A - インフルエンザのノイラミニダーゼに対する広域中和抗体 - Google Patents

インフルエンザのノイラミニダーゼに対する広域中和抗体 Download PDF

Info

Publication number
JP2023551668A
JP2023551668A JP2023531064A JP2023531064A JP2023551668A JP 2023551668 A JP2023551668 A JP 2023551668A JP 2023531064 A JP2023531064 A JP 2023531064A JP 2023531064 A JP2023531064 A JP 2023531064A JP 2023551668 A JP2023551668 A JP 2023551668A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551668A5 (enExample
Inventor
コルティ ダビデ
サムエーレ ピッツト マッテオ
ミノラ アンドレア
カメローニ エリザベッタ
スネル ジョージー
フェリ エレナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Vir Biotechnology Inc
Original Assignee
Humabs Biomed SA
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA, Vir Biotechnology Inc filed Critical Humabs Biomed SA
Publication of JP2023551668A publication Critical patent/JP2023551668A/ja
Publication of JP2023551668A5 publication Critical patent/JP2023551668A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023531064A 2020-11-23 2021-11-19 インフルエンザのノイラミニダーゼに対する広域中和抗体 Pending JP2023551668A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063117448P 2020-11-23 2020-11-23
US63/117,448 2020-11-23
US202063123424P 2020-12-09 2020-12-09
US63/123,424 2020-12-09
US202163197160P 2021-06-04 2021-06-04
US63/197,160 2021-06-04
US202163261463P 2021-09-21 2021-09-21
US63/261,463 2021-09-21
PCT/US2021/060155 WO2022109309A1 (en) 2020-11-23 2021-11-19 Broadly neutralizing antibodies against influenza neuraminidase

Publications (2)

Publication Number Publication Date
JP2023551668A true JP2023551668A (ja) 2023-12-12
JP2023551668A5 JP2023551668A5 (enExample) 2024-11-08

Family

ID=79021106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531064A Pending JP2023551668A (ja) 2020-11-23 2021-11-19 インフルエンザのノイラミニダーゼに対する広域中和抗体

Country Status (13)

Country Link
US (1) US20240092876A1 (enExample)
EP (1) EP4247495A1 (enExample)
JP (1) JP2023551668A (enExample)
KR (1) KR20230137293A (enExample)
AU (1) AU2021381778A1 (enExample)
CA (1) CA3199023A1 (enExample)
CL (1) CL2023001462A1 (enExample)
CO (1) CO2023007527A2 (enExample)
IL (1) IL302963A (enExample)
MX (1) MX2023005654A (enExample)
PH (1) PH12023551390A1 (enExample)
TW (1) TW202229329A (enExample)
WO (1) WO2022109309A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260184814A1 (en) * 2022-05-23 2026-07-02 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
AU2023358546A1 (en) * 2022-10-14 2025-05-29 Longhorn Vaccines And Diagnostics, Llc Vaccines and antibodies for the treatment and prevention of microbial infections
WO2026021428A1 (en) * 2024-07-23 2026-01-29 Westlake University Anti-neuraminidase antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213384A1 (en) * 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7803C (enExample)
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10072070B2 (en) * 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213384A1 (en) * 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 441, JPN6025041155, 2013, pages 226 - 229, ISSN: 0005703240 *
SCIENCE, vol. 366, JPN6025041154, 2019, pages 499 - 504, ISSN: 0005849498 *

Also Published As

Publication number Publication date
AU2021381778A9 (en) 2025-01-09
KR20230137293A (ko) 2023-10-04
CL2023001462A1 (es) 2023-10-20
CA3199023A1 (en) 2022-05-27
WO2022109309A9 (en) 2022-09-01
US20240092876A1 (en) 2024-03-21
TW202229329A (zh) 2022-08-01
PH12023551390A1 (en) 2023-12-04
WO2022109309A1 (en) 2022-05-27
MX2023005654A (es) 2023-07-31
IL302963A (en) 2023-07-01
EP4247495A1 (en) 2023-09-27
CO2023007527A2 (es) 2023-08-18
AU2021381778A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP2023523549A (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
WO2021247925A1 (en) Structure-guided immunotherapy against sars-cov-2
WO2022204202A1 (en) Antibodies that bind to multiple sarbecoviruses
US20240092876A1 (en) Broadly neutralizing antibodies against influenza neuraminidase
US20240141021A1 (en) Anti-influenza antibodies and combinations thereof
TWI901812B (zh) 針對a型流感病毒的抗體
JP2025522295A (ja) インフルエンザノイラミニダーゼに対する広域中和抗体
WO2023230448A1 (en) Combination immunotherapy for influenza
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
TW202423963A (zh) 針對ｒｓｖ及ｍｐｖ副黏液病毒之廣效中和抗體
CN116888157A (zh) 针对流感神经氨酸苷酶的广泛中和抗体
EA051192B1 (ru) Антитела против вирусов гриппа а
CN116981687A (zh) 针对甲型流感病毒的抗体
CN116997567A (zh) 抗流感抗体和其组合
WO2024215762A1 (en) Antibodies that bind to multiple sarbecoviruses
WO2024086566A2 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241030

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260428